RPRX Royalty Pharma plc
USHealthcareAs of 2026-07-10 16:00
Why RPRX matters now
Royalty Pharma plc (RPRX) is a US stock in Healthcare. The latest InvestLog snapshot shows $56.43 with -2.64% on the session and $24.27B in market capitalization; recent performance reads 1-month +1.05% and YTD +37.06%.
The latest financial table shown here is Q1 2026, with revenue of $630.6M, net income of $295.0M, and EPS of $0.53. Investors can compare that operating picture with valuation signals such as P/E 26.05 and FCF yield 11.7%.
The latest indexable market news headline is "Why Royalty Pharma (RPRX) Could Beat Earnings Estimates Again" from Zacks Investment Research.
Additional event context on this page matters because analyst consensus is Buy with a median target of $57.00; recent insider activity includes Bassler Bonnie L filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
26.05
PEG
—
P/B
3.32
P/S
9.33
EV/EBITDA
18.34
DCF Value
$25.28
FCF Yield
11.7%
Div Yield
1.7%
Margins & Returns
Gross Margin
100.0%
Operating Margin
67.9%
Net Margin
33.9%
ROE
12.7%
ROA
4.2%
ROIC
8.4%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $630.6M | $295.0M | $0.53 |
| Q4 2025 | $622.0M | $214.2M | $0.50 |
| FY 2025 | $2.38B | $770.9M | $1.80 |
| Q3 2025 | $609.3M | $288.2M | $0.67 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$56.67
Target (Median)
$57.00
Target Range
$50.00 - $63.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.42
Royalty Pharma plc, headquartered in New York City and founded in 1996, operates within the United States as a key player in the biopharmaceutical industry. The company primarily focuses on the acquisition of royalties from biopharmaceutical products and actively invests in funding new developments and innovations in the sector. Its activities involve diligently identifying, evaluating, and securing royalty agreements for a wide array of biopharmaceutical therapies. Beyond acquisitions, Royalty Pharma plc fosters collaborations with various innovators. These partners include academic institutions, research hospitals, non-profit organizations, small and mid-sized biotechnology firms, and larger pharmaceutical companies. The firm's substantial portfolio includes royalty interests in approximately 35 commercially available treatments and an additional 10 product candidates currently in different stages of development. These assets span a diverse range of critical therapeutic areas, such as rare diseases, cancer, neurological conditions, infectious diseases, hematology, and diabetes.